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Background: Haemophilus parasuis (H. parasuis) causes Glässer’s disease and multisystem infectious disease. It is
one of the major causes of nursery mortality in swine herds. Cefquinome (CEQ) is proposed for the treatment of
pigs against respiratory tract infection. However, few studies have investigated the PK/PD characteristics and PK/PD
cutoff of this drug against H. parasuis.
Results: A total of 213 H. parasuis strains were isolated from diseased pigs in China. The minimal inhibitory
concentrations (MICs) of CEQ against these isolates were determined. The MIC50 and MIC90 values were 0.125 and
8 mg/L, respectively. An in vitro dynamic PK/PD infection model was used to investigate the antimicrobial effect of
CEQ against H. parasuis strain of serotype 5. The target values of CEQ for 3-log10-unit and 4-log10-unit decreases
effects were the percent time that CEQ concentrations were above the minimum inhibitory concentration (T% >
MIC) of 61 and 71 respectively. According to Monte Carlo simulation, the PK/PD cutoff for CEQ against H. parasuis
was 0.06 mg/L. The suggested dose regimen was 4 mg/kg/12 h BW.
Conclusions: The value of PK/PD surrogate marker T% >MIC is of great utility in CEQ clinical usage. The very first
CEQ PK/PD cutoff provide fundamental data for CEQ breakpoint determination. A more desirable dose regimen
against H. parasuis was provided for CEQ using in China district.
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H. parasuis is a commensal bacterium of the upper re-
spiratory tract of swine [1]. Under certain conditions, H.
parasuis can invade the body and cause Glässer’s disease
as well as other severe diseases, such as arthritis, fibrin-
ous polyserositis and meningitis [2]. Moreover, H. para-
suis can invade into the AOC-45 porcine aorta
endothelial cells [3] and its endotoxin is able to induce* Correspondence: gale@scau.edu.cn
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unless otherwise stated.disseminated intravascular coagulation, which results in
the formation of microthrombi in some important or-
gans [2]. In addition, H. parasuis frequently interacts
with porcine reproductive respiratory syndrome virus
(PRRSv) and causes more economic losses [4,5]. H.
parasuis has numerous serovars, some of which show
severe virulence and cause death within 4 days such as
serovar 1, 5, 10, 12, 13 and 14 [6]. Of them, serovar 5
and 4 are the most prevalent types isolated in China [7],
Danmark [8], Germany [6], the USA [9], Japan [10] and
Spain [11], whereas serovars 5 and 13 are prevalent in
Australia [12]. Due to the serovar diversity and lack of
cross-reaction among the serovars, it is hard to develop
an effective cross-protective vaccine [13]. Thereforeis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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H. parasuis infections.
Cefquinome (CEQ) is a fourth generation cephalo-
sporin antibiotic that is solely developed for veterinary
use. It possesses high stability to β-lactamases and is ac-
tive against Gram-positive and Gram-negative bacteria.
The European Medicines Agency (EMA) proposes CEQ
for the treatment of pigs against respiratory tract infec-
tions with a dosage regimen of 2 mg/kg/24 h bodyweight
(BW) for three to five days [14]. As one of the major
pathogens of respiratory tract of pigs, few studies have
investigated the killing pattern and PK/PD characteris-
tics of this drug against H. parasuis, moreover, the
Clinical and Laboratory Standards Institute (CLSI) sub-
committee on Veterinary Antimicrobial Susceptibility
Testing (VAST) which establishes veterinary clinically
breakpoints [15] has not established breakpoints for H.
parasuis. The value of PK/PD surrogate which is of great
utility in CEQ clinical usage and the CEQ PK/PD cutoff
providing fundamental data for CEQ breakpoint deter-
mination should be illuminated.
In this study, the minimal inhibitory concentrations
(MICs) of CEQ against 213 H. parasuis isolates identi-
fied in China were determined. An in vitro PK/PD
infection model has been used to investigate the anti-
microbial effect of CEQ against H. parasuis strain of
serotype 5, which is highly virulent and one of the most
prevalent serotypes in China [7]. A 5,000-subjects Monte
Carlo simulation has been done to derive a PK/PD cutoff
based on three aspects: MIC distributions of CEQ
against H. parasuis, pharmacokinetic/pharmacodynamic
(PK/PD) indices and Pharmacokinetics of CEQ in swine
obtained in a previous study [16]. A more rational regi-




All husbandry practices and experimental operations
were performed with full consideration of animal wel-
fare. Research ethical approval was granted by the South
China Agriculture University Animal ethics committee
(2014-03).
Strains and antibiotic
H. parasuis strain representing serovar 5 was kindly pro-
vided by Professor Ming Liao, College of Veterinary Medi-
cine, South China Agricultural University, Guangzhou,
Guangdong Province, China. It was CEQ sensitive to MIC
of 0.003 mg/L. The other 213 H. parasuis isolates used in
this study were derived from diseased pigs suffering fibrin-
ous polyserositis, meningitis and polyarthritis diagnosed
in China during August 2010 to July 2011. Serotypes of
these isolates are not known. All the strains were storedat −80°C in milk. Prior to use, they were streaked on a
tryptone soya agar (TSA) (Oxoid Ltd., Basingstoke,
Hampshire, UK) added with 5% new-born calf serum
(Guangzhou Ruite Bio-tec Co., Ltd., Guangdong, China)
and 2% beta-Nicotinamide adenine dinucleotide trihydrate
(NAD) (Qingdao Hope Bio-Technology Co., Ltd.,
Shandong, China). Tryptone soya broth (Oxoid Ltd.,
Basingstoke, Hampshire, UK) added with the same
amount of NAD and new-born calf serum was used to
culture H. parasuis. CEQ sulfate injection (25 mg/mL)
was purchased from Hebei Yuanzheng Pharmaceutical
Company (Hebei, China).MICs
Given the unavailability of a CLSI approval method for
H. parasuis, MICs were conducted in accordance with
the CLSI VET01-A4 recommendations for Actinobacil-
lus pleuropneumoniae [17]. The quality control strain
was Actinobacillus pleuropneumoniae ATCC 27090. The
values of MIC50 and MIC90, inhibiting the growth of at
least 50% and 90% of isolates in a test population, re-
spectively, were calculated in this study following the
methods previously published [18].In vitro dynamic PK/PD modeling
The in vitro one-compartment PK/PD infection model
was constructed according to previously described
method [19] with some improvements. The model
system contained fresh trypticase soy broth reservoir,
central compartment and waste storage compartment.
These compartments were connected with silicone
tubes. The broth was pumped from the reservoir to the
central compartment through a peristaltic pump, which
is controlled digitally. An inverted 15-mL centrifuge tube
with a cellulose ester membrane (0.2-μm pore size) cov-
ering the top was placed in the central compartment to
prevent bacteria from flowing out to the medium. Below
the membrane, a magnetic stir bar was placed on the
bottom of the central compartment. The stir bar mixed
the broth and enabled the drug to fully contact with the
bacteria. The temperature of the reservoir and central
compartment was controlled between 36 and 37°C via
water bath. The entire experimental system was placed
in a UV-sterilized worktable. The reservoir and central
compartment contained 700 and 60 mL of trypticase soy
broth, respectively. Fresh broth pumped into the central
compartment, and the same volume culture media
pumped into the waste container. To simulate intraven-
ous injection pharamcokinetics of CEQ in swine with
this equipment, the flow rate was 0.37 mL/min. The
drug was administered into the central compartment via
the sampling port at zero time point.
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A 12 h culture of bacteria with optical density (OD)
value of approximately 0.09 was added to the central
compartment [107 colony forming unit (cfu)/mL] and
incubated at 35°C to 37°C for 30 min to condition the
bacteria to the new environment. Different doses of
CEQ (0.28, 0.68, 4.03, 9.79, 15.26, 37.08, 90.13, 140.50,
219.03, 341.45 μg) or control (sterile normal saline) were
introduced into the central compartment, and the peri-
staltic pump was turned on immediately. A 150 μL
aliquot was obtained for bacterial counting at time
points of 0, 3, 6, 9, 12 and 24 h. Samples were diluted
properly with sterile normal saline, and 25-μL of aliquots
of the last four diluted samples were plated onto the
TSA plates and incubated at 37°C for 24 h. To monitor
drug concentrations, 200-μL aliquots were also obtained
at 1, 6, 12 and 24 h and centrifuged at 8,000 rpm at 4°C
for 10 min. The supernatant was stored at −80°C and
analyzed within 1 month. All experiments were per-
formed in duplicate on different days.Table 1 Serum pharmacokinetic parameters after IV
administration at 2 mg/kg bodyweight in a two-compartment
open model used for Monte Carlo simulation
Parameter (units) Mean value SD
T1/2ka (h) 0.06 0.03
T1/2β (h) 2.34 0.09
CL/F(L/kg) 0.09 0.03
F(%) 116.29 14.72Pharmacokinetics and PK/PD analysis
The samples were analyzed for CEQ concentration using
the method reported previously [19]. The PK data were
analyzed using Phoenix WinNonlin 6.0 software (Phar-
sight Co. Ltd.). A T% >MIC value during a 24-h interval
was calculated using the pharmacokinetic and MIC data
for each time kill curve. The in vitro drug effect was
quantified by changes in log10 cfu counts between 24
and 0 h. Data were analyzed using sigmoid Emax model
WINNONLIN software (version 6.1; Pharsight, CA,
USA) per the following equation:




where E0 is the change in log10 cfu/mL after 24-h incu-
bation in the control sample compared to the initial
inoculum. Emax is the difference in effect between the
greatest amount of growth (as seen for the growth con-
trol, E0) and the greatest amount of kill. Ce is the T% >
MIC in the effect compartment. EC50 is the T% >MIC
value producing a 50% reduction in bacterial counts
from the initial inoculum, and N is the Hill coefficient
that describes the steepness of the T% >MIC–effect
curve. Three levels of growth inhibition were calculated.
T% >MIC for bacteriostatic and bactericidal actions are
values that produce E = 0 (no change in bacterial counts
after 24 h incubation) and E = − 3 (a 3 log10 or 99.9%
reduction of the original inoculum counts after 24 h in-
cubation), respectively. Bacterial eradication is the lowest
T% >MIC that provides a 4 log10 reduction.Monte Carlo simulation
Based on a previous pharmacokinetic study of CEQ in
pigs [19], MIC distribution, and the value of PK/PD
target indices obtained in this study, a 5,000-subjects
Monte Carlo simulation was conducted using Crystal
Ball Professional V7.2.2 software. The time above MIC





Where C is the value of MIC, ka is the absorption half
life, F is the bioavailability, X0 is the dose of antibiotic
and k is the elimination half life.
All the PK parameters were assumed to be normally
distributed in the form of mean values and confidence
intervals (Table 1). MICs were fixed at single values
from 0.0015 mg/L to 16 mg/L. The PK/PD cutoff is the
MIC, at which the probability of target attainment
(PTA) for 3-log10-unit decrease equals 90% under clin-
ical recommended dose. Scenarios were simulated separ-
ately for the IM administration, which were single-dose
administrations of 2, 4, 8, 16, 32 and 60 mg/kg BW and
doses of 1, 2, 4, 6, 8 and 16 mg/kg BW administered in
two equal doses at 12-h interval.
Results
MIC distribution
MICs of CEQ against 213 H. parasuis isolates were di-
verse, ranging from 0.0015 mg/L to 16 mg/L. The per-
centages for each MIC (0.0015, 0.003, 0.006, 0.015, 0.03,
0.06, 0.125, 0.25, 0.5, 1, 2, 4, 8 and 16 mg/L) were 1.48%,
0.96%, 2.95%, 3.94%, 13.79%, 16.75%, 17.73%, 19.21%,
2.96%, 5.42%, 0.99%, 2.46%, 7.39% and 3.94%, respect-
ively (Figure 1). Although a low peak of MIC was
observed at 8 mg/L, the MICs distributed in a normal
distribution pattern basically with a definite peak at 0.25
mg/L. The MIC50 and MIC90 were determined to be
0.125 and 8 mg/L, respectively.
In vitro dynamic PK/PD modeling
The pharmacokinetics of CEQ in pigs was well simulated
by this in vitro model with a relative deviation below 6%.
For bacterial counting, the limit of determination was 400
Figure 1 Minimum inhibitory concentrations (MIC) of cefquinome
against H. parasuis. (213 strains in total).
Figure 3 Sigmoid Emax model relationships between
antimycoplasmal effect [E, log10 (cfu/mL)] and T% >MIC of
cefquinome in in vitro PK/PD model against H. parasuis with
an inoculum size of 1 × 107 cfu/mL.
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T% >MIC values were equal to or below 15 within 24 h
(Figure 2). When T% >MIC value were 35 and 50, CEQ
gained a 3-log10-unit and a 4-log10-unit decrease, respect-
ively, at 9 h to 12 h, but regrowth was observed at 24 h.
When T% >MIC increased to the values of 60 and 70,
CEQ completely killed H. parasuis without regrowth in
24 h (3-log-unit and 4-log-unit decrease, respectively).
CEQ is considered to be a time-dependent drug. The
in vitro antimicrobial effect of CEQ was described suc-
cessfully using sigmoid Emax model by the suitable PK/PD
surrogate marker T% >MIC (Figure 3). The estimated E0,
EC50 and Emax are listed in Table 2. The target values of
3-log10-unit and 4-log10-unit decreases for T% >MIC were
61 and 71, respectively.
Monte Carlo simulation
The PTAs following CEQ administration at dose of 2 mg/
kg/24 h was shown in Figure 4. For the recommendedFigure 2 Time–kill curve of cefquinome against H. parasuis in in vitro2 mg/kg/24 h BW dose administered by IM, PTA > 90%
could only be achieved for MIC < 0.06 mg/L. That is to
say, the PK/PD cutoff for CEQ against H. parasuis was
0.06 mg/L. The PTAs for each effect and the PK/PD cut-
offs with different drug regimens are listed in Table 3. A
recommended single IM administration of CEQ dose
(2 mg/kg/24 h BW) could not achieve PTA > 90%, neither
did an increased dose of 60 mg/kg/24 h BW for all the
strains used in this study. However, a PTA of 90.03% was
acquired by splitting the daily dose of (32 mg/kg/24 h
BW) into two equal doses given at a 12-h interval (16 mg/
kg/12 h). In consideration of the PTA (85.79%) following
CEQ administration at dose of 4 mg/kg/12 h, which was
close to 90%, the recommended dose regimen was defined
as 4 mg/kg/12 h. The PTAs following CEQ administration
at dose of 4 mg/kg/12 h was shown in Figure 5.PK/PD model.
Table 2 Pharmacodynamic analysis of data acquired from
in vitro time-killing studies for cefquinome against
H. parasuis
Parameter (units) Value
Log Emax (cfu/mL) −4.7
Log E0 (cfu/mL) 1.6
EC50 (h) 48.9
T% >MIC (bacteriostatic) (h) 38.7
T% >MIC (bactericidal) (h) 60.9
T% >MIC (bacterial elimination) (h) 70.9
Slope (N) 4.7
Where E0 is the change in log10 cfu/mL after 24 h incubation in the control
sample compared to the initial inoculum. Emax is the difference in effect
between the greatest amount of growth (as seen for the growth control, E0)
and the greatest amount of kill. Ce is the T% >MIC in the effect compartment.
EC50 is the T% >MIC value producing a 50% reduction in bacterial counts from
the initial inoculum, and N is the Hill coefficient that describes the steepness
of the T% >MIC–effect curve.
Table 3 Probability of target attainment (PTA) and
breakpoints of cefquinome against H. parasuis with
recommended regimens (2 mg/kg/24 h and 4 mg/kg/12 h)
Drug regimens PTA for
T% >MIC = 61
PTA for
T% >MIC = 71
Susceptibility
breakpoint (mg/L)
1 mg/kg/12 h 76.87 72.52 0.3
2 mg/kg/12 h 82.19 80.63 0.6
4 mg/kg/12 h 85.79 84.37 1.3
6 mg/kg/12 h 86.46 85.88 1.9
8 mg/kg/12 h 87.64 86.76 2.6
16 mg/kg/12 h 90.03 88.55 5.2
2 mg/kg/24 h 44.79 28.18 0.06
4 mg/kg/24 h 61.77 43.52 0.15
8 mg/kg/24 h 76.91 61.6 0.3
16 mg/kg/24 h 81.25 77.21 0.6
32 mg/kg/24 h 86.06 82.21 1.2
60 mg/kg/24 h 86.64 84.74 2.2
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H. parasuis frequently causes Glässer’s disease, which is
often treated with sulfanilamide, quinolones and cepha-
losporins. However, with these drugs wildly used, the re-
sistant H. parasuis isolates are emerging quickly [20].
The most important factor in resistance emergence and
spread is drug exposure, especially, the exposure to sub-
therapeutic drug concentrations [21]. The PK/PD model-
ing determines the exposure-activity relationships. Using
the regimens based on appropriate PK/PD targets will pre-
vent the emergence of resistance [22]. So it is of great
importance to administer antibiotics to animals using regi-
mens that will attain appropriate PK/PD targets [23]. In
this PK/PD analysis, T% >MIC which was considered as
the PK/PD index of most cephalosporins [24] correlated
well with in vitro drug efficiency. Through the Sigmoid
Emax modeling, the PK/PD target for bactericidal effect
and elimination action was T% >MIC = 61 and 71, re-
spectively. The results reported here were highly consist-
ent with the published data that the greatest efficacy ofFigure 4 Probability of target attainment (PTA) for the
treatment with cefquinome dose of 2 mg/kg/24 h.cephalosporins in several animal infection models could
be achieved as the value of T% >MIC reached 60% - 70%
of the dosing interval against Streptococci or Enterobacte-
riaceae [25].
PK/PD cutoffs are important tools to set susceptibility
breakpoints, which have also been used by regulatory
agencies, such as EUCAST and VAST, to refine the sus-
ceptibility breakpoint [26]. Monte Carlo simulation pro-
vides great advantage using drug exposure–effect
relationship [27] which considers pharmacokinetic vari-
ation in target animals, MIC distribution and PK/PD in-
dices in defining the PK/PD cutoffs. The PK/PD cutoff
of CEQ against H. parasuis was 0.06 mg/L under EMA
recommended dosage (2 mg/kg/day). This PK/PD cutoff
value was similar with the clinical breakpoint values of
cefotaxime, a third generation cephalosporin antibiotic,
against Pasteurella multocida (0.03 mg/L) or NeisseriaFigure 5 Probability of target attainment (PTA) for the
treatment with cefquinome dose of 4 mg/kg/12 h.
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values of clinical breakpoints of cefotaxime (0.12 mg/L),
ceftriaxone (0.12 mg/L), cefixime (0.12 mg/L), cefpodox-
ime (0.25 mg/L) and ceftaroline (0.03 mg/L) against
Haemophilus influenzae, another bacteria of Haemophi-
lus spp. in human clinic (EUCAST, 2014) [28]. However,
this breakpoint was much lower than the PK/PD cutoff
of cefotaxime (1 mg/L), ceftriaxone (1 mg/L), ceftazi-
dime (4 mg/L) and cefepime (4 mg/L) (EUCAST, 2014)
[28]. As the half-life and the PK/PD targets of CEQ are
almost identical with those of the cephalosporins (1.5-
2.5 h) [25,29], the main reason for the difference may re-
sult from the dosing interval. PK/PD cutoff values for
those drugs were based on drugs administered two or
three times one day except ceftriaxone while single dose
administration as recommended by EMA was chose in
this study for CEQ. Compared to single dosing, the con-
centrations of these drugs after administration with mul-
tiple doses within 24 h could maintain a relatively high
level, resulting in a higher MIC value of threshold for
attaining the same T% >MIC value. Though the PK/PD
cutoff had been determined, to establish a susceptibility
breakpoint of CEQ, the clinical data are needed.
Under recommended dose regimen of 2 mg/kg/24 h,
the PTAs for reach the T% >MIC of 61 and 71 were
44.8% and 28.2%. This seems to indicate that only less
than half of the infections could be cured and less than
a third of infections could be bacterial eradicated. In
order to improve clinical response to therapy and reduce
selection pressure for antimicrobial resistance during
therapy, increasing doses were needed. With the increas-
ing of the total amount of drug, the PTA increased ac-
cordingly in both single doses and 2 splitting dose
regimens. However, the same daily amount of CEQ ad-
ministered once-daily or twice-daily, such as 1 mg/kg/12
h and 2 mg/kg/24 h, resulted in different PTAs (76.87%
and 44.79%, respectively) implying that splitting dose
would reach higher PTA than a single dose administra-
tion. Moreover, compared to the dose splitting scenario,
the PTA increased much less under single dosing, al-
though the total amount of drug was increased. Therefore,
dosing interval change, such as daily dose splitting, offers
a much more attractive strategy in improving the clinical
curing rate. Similar conclusion was conducted in cefprozil
against H. influenzae that once daily dosing of cefprozil
provided less activity compared with twice daily [30].
A theoretical regimen (i.e., 16 mg/kg/12 h) was recom-
mended based on the PTA for T% >MIC of 61 over
90%. However, considering the economic impact and the
therapeutic outcome, 4 mg/kg/12 h is suggested as a
more suitable dose regimen, which is less expensive for
farmers, but its PTA (85.79%) for T% >MIC of 61 is
closer to 90%. Additionally, a much less drug amount
dosage can be more eco-friendly, cost-effective andminimize the drug residue burden on public health via
human food consumption.
Under the EMA recommended regimen, because of
the single dose and short elimination half-life of CEQ,
the derived PK/PD cutoff was 0.06 mg/L. It was lower
than MIC50 (0.125 mg/L) of isolates from China. This
result indicates that no more than half of the infection
in China district could use CEQ for curing under recom-
mend regimen. While, for the dose of 4 mg/kg/12 h rec-
ommended in this study, the PK/PD cutoff was 1.3 mg/L.
Though it didn’t cover all the MIC value, it covered more
than 85% of the MIC distribution. Howerver, one point
should be paid attention to is that the strains used in this
simulation were limited in china. It cannot stand for the
MIC distribution of the world. For international CEQ
dose regimen against H. parasuis, more MICs of H. para-
suis strains in a worldwide scale should be taken into ac-
count. Although further clinical studies are needed to
confirm the modelling results, the present study could
provide fundamental data for CEQ susceptibility test and
improve the use of CEQ for swine health to a certain
extent.Conclusions
In conclusion, this study established an in vitro dynamic
PK/PD modelling of CEQ against H. parasuis. The target
values of CEQ for 3-log10-unit and 4-log10-unit de-
creases effects were T% >MIC of 61 and 71 respectively.
The very first CEQ PK/PD cutoff (0.06 mg/L) which is
of great utility in CEQ susceptibility breakpoint deter-
mination and dosing design were derived based on
Monte Carlo simulation. A more desirable dose regimen
against H. parasuis was determined to be 4 mg/kg/12 h
in China.
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